Blends
Marketed mixtures, not molecules
KLOW, GLOW, Wolverine and similar names are nicknames given by whoever is selling a vial — not standardised medicines. These records explain what each name usually refers to, what is unknown about the formulation, and why the evidence behind the ingredients is not evidence behind the mixture.
A marketed blend name is not a standard formulation.
Blends are mixtures sold under a nickname. The name is chosen by whoever is selling it, so two vials with the same name can contain different ingredients in different amounts. Any evidence level shown here describes the combined marketed mixture, which is almost always untested as a mixture.
4 blends in the curated record
Blend records
KLOW
A marketed injectable mixture usually described as KPV, GHK-Cu, BPC-157 and TB-500 together, sold as an all-round repair and skin blend.
Commonly marketed as: KPV + GHK-Cu + BPC-157 + TB-500
A marketed blend name is not a standard formulation.
Wolverine
A marketed injectable mixture usually described as BPC-157 plus TB-500, sold on a fast-healing theme.
Commonly marketed as: BPC-157 + TB-500
A marketed blend name is not a standard formulation.
GLOW
A marketed injectable mixture usually described as GHK-Cu, BPC-157 and TB-500, sold on skin, hair and recovery themes.
Commonly marketed as: GHK-Cu + BPC-157 + TB-500
A marketed blend name is not a standard formulation.
CJC-1295 + Ipamorelin
The most commonly marketed growth-hormone-axis pairing: a GHRH-type peptide combined with a ghrelin-receptor secretagogue.
Commonly marketed as: CJC-1295 + Ipamorelin
A marketed blend name is not a standard formulation.
Why blends get their own area
Treating a blend nickname as though it were a compound quietly implies it has been studied as one. It hasn’t. Keeping blends separate lets each ingredient keep its own honest evidence position on its own profile, while the mixture is recorded for what it is: an untested, unstandardised product.